Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

May 28, 2024

Study Completion Date

September 1, 2025

Conditions

Non-small Cell Lung CancerStage II-IIIAImmunotherapyNeoadjuvant Therapy

Interventions

DRUG

Serplulimab and Chemotherapy

Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER